{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0","value":"0.0"},{"groupId":"OG001","spread":"0.00","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Cycle 1 Day 1: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.34","value":"2.1"},{"groupId":"OG001","spread":"1.13","value":"2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Cycle 1 Day 2: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.42","value":"3.2"},{"groupId":"OG001","spread":"2.98","value":"5.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"Cycle 1 Day 15: Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.96","value":"2.8"},{"groupId":"OG001","spread":"2.73","value":"4.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"Cycle 1 Day 22: Pre-dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"description":"Trough concentrations of everolimus was quantified using validated liquid LC-MS/MS methods.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with recurrent or refractory solid tumors received lenvatinib 8 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily in cycle 1 (each cycle was 28 days) until the occurrence of PD, clinical benefit, development of unacceptable toxicity leading to withdrawal from the study, study discontinuation or for a maximum of 18 cycles (each cycle was 28 days) whichever occurred first.","id":"OG000","title":"Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2"},{"description":"Participants with recurrent or refractory solid tumors received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily in cycle 1 (each cycle was 28 days) until the occurrence of PD, clinical benefit, development of unacceptable toxicity leading to withdrawal from the study, study discontinuation or for a maximum of 18 cycles (each cycle was 28 days) whichever occurred first.","id":"OG001","title":"Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic analysis set included participants who had at least one measurable postdose plasma concentration with an adequately documented drug administration history. Here, 'overall number of participants analyzed' signifies participants who were evaluable for this outcome measure and 'number analyzed' signifies participants who were evaluable for given timepoints of this outcome measure. Pharmacokinetic data was planned to be analyzed for Phase 1 only.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Days 1, 2, 15 and 22: Pre-dose (Cycle length=28 days)","title":"Phase 1: Trough Concentrations (Ctrough) of Everolimus When Administered in Combination With Lenvatinib","type":"SECONDARY","unitOfMeasure":"ng/mL"}